Subtopic Deep Dive

← Plant Toxicity and Pharmacological Properties

Hepatic Sinusoidal Obstruction Syndrome Pyrrolizidine Alkaloids
Research Guide

What is Hepatic Sinusoidal Obstruction Syndrome Pyrrolizidine Alkaloids?

Hepatic Sinusoidal Obstruction Syndrome (HSOS) induced by pyrrolizidine alkaloids (PAs) is a veno-occlusive liver disease caused by endothelial damage from PA-containing herbal products.

HSOS features sinusoidal congestion, hepatocyte necrosis, and clinical ascites from PA toxicity in herbs like comfrey and Tusanqi. Research identifies blood pyrrole-protein adducts (PPAs) as diagnostic biomarkers (Gao et al., 2011, 109 citations; Gao et al., 2015, 65 citations). Over 1,200 citations across 10 key papers document histopathological and imaging features.

Curated Papers

Key Challenges

Why It Matters

HSOS from PAs causes outbreaks via contaminated teas and supplements, as in cases linked to Tusanqi (Gao et al., 2011). Early PPA detection improves prognosis (Gao et al., 2015), while imaging aids severity grading (Zhou et al., 2014, 79 citations). Ridker et al. (1985, 186 citations) and Huxtable (1992, 166 citations) highlight risks in dietary supplements, guiding regulatory bans on PA herbs like comfrey (Stickel and Seitz, 2000, 156 citations).

Key Research Challenges

Diagnostic Specificity

Distinguishing PA-HSOS from other liver diseases relies on PPA tests, but sensitivity varies by exposure timing (Gao et al., 2011). Chojkier (2003, 130 citations) notes histopathological overlap with viral hepatitis. Gao et al. (2015) correlate PPA levels to outcomes, yet thresholds need refinement.

Toxicity Mechanisms

PAs form reactive pyrroles damaging sinusoids, but dose-response differs across herbs (Neuman et al., 2015, 108 citations). Huxtable (1992) warns of underreported herbal risks. Valla and Cazals-Hatem (2016, 123 citations) describe variable endothelial responses.

Therapeutic Interventions

No specific antidote exists; defibrotide shows promise but lacks PA-specific trials (Chojkier, 2003). Zhou et al. (2014) link imaging severity to poor recovery. Larrey and Faure (2010, 68 citations) call for biomarker-guided therapies.

Essential Papers

Hepatic Venocclusive Disease Associated With the Consumption of Pyrrolizidine Containing Dietary Supplements

Paul M. Ridker, Seitaro Ohkuma, William V. McDermott et al. · 1985 · Gastroenterology · 186 citations

The Myth of Beneficent Nature: The Risks of Herbal Preparations

Ryan J. Huxtable · 1992 · Annals of Internal Medicine · 166 citations

Editorials15 July 1992The Myth of Beneficent Nature: The Risks of Herbal PreparationsRyan J. Huxtable, PhDRyan J. Huxtable, PhDSearch for more papers by this authorAuthor, Article, and Disclosure I...

The efficacy and safety of comfrey

Felix Stickel, Helmut K. Seitz · 2000 · Public Health Nutrition · 156 citations

Abstract Herbal medication has gathered increasing recognition in recent years with regard to both treatment options and health hazards. Pyrrolizidine alkaloids have been associated with substantia...

Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids

Mario Chojkier · 2003 · Journal of Hepatology · 130 citations

Sinusoidal obstruction syndrome

Dominique Valla, Dominique Cazals‐Hatem · 2016 · Clinics and Research in Hepatology and Gastroenterology · 123 citations

Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids

Hong Gao, Na Li, Ji Yao Wang et al. · 2011 · Journal of Digestive Diseases · 109 citations

OBJECTIVE: Hepatic sinusoidal obstruction syndrome (HSOS) induced by a Chinese medicinal herb Tusanqi is increasingly being reported in recent years. The aim of the study was to investigate the pos...

Hepatotoxicity of Pyrrolizidine Alkaloids

Manuela G. Neuman, Lawrence Cohen, Mihai Opris et al. · 2015 · Journal of Pharmacy & Pharmaceutical Sciences · 108 citations

PURPOSE: This article aimed 1) to review herbal medicine containing pyrrolizidine alkaloids (PA)-induced toxicities of the liver; 2) to encourage the recognition and prevention of common problems e...

Reading Guide

Foundational Papers

Start with Ridker et al. (1985, 186 citations) for clinical cases, Huxtable (1992, 166 citations) for herbal risks, Chojkier (2003, 130 citations) for toxicity mechanisms.

Recent Advances

Study Gao et al. (2015, 65 citations) for PPA prognostics, Zhou et al. (2014, 79 citations) for imaging, Valla and Cazals-Hatem (2016, 123 citations) for syndrome overview.

Core Methods

PPA detection via UPLC-MS/MS (Gao et al., 2011); CT/MRI for patchy enhancement and vein narrowing (Zhou et al., 2014); histopathology for sinusoidal obstruction (Chojkier, 2003).

How PapersFlow Helps You Research Hepatic Sinusoidal Obstruction Syndrome Pyrrolizidine Alkaloids

Discover & Search

Research Agent uses searchPapers and exaSearch to find PA-HSOS papers like Gao et al. (2011), then citationGraph reveals Huxtable (1992, 166 citations) as a hub connecting 186-cited Ridker et al. (1985) to recent works; findSimilarPapers expands to Tusanqi cases.

Analyze & Verify

Analysis Agent applies readPaperContent to extract PPA thresholds from Gao et al. (2015), verifies claims via CoVe against Neuman et al. (2015), and runs PythonAnalysis on citation data with pandas for severity correlations; GRADE scores evidence as high for biomarkers (Gao et al., 2011).

Synthesize & Write

Synthesis Agent detects gaps in therapeutic trials post-Chojkier (2003), flags contradictions in comfrey safety (Stickel and Seitz, 2000); Writing Agent uses latexEditText, latexSyncCitations for HSOS review, and latexCompile for publication-ready manuscript with exportMermaid timelines of outbreaks.

Use Cases

"Analyze PPA concentration trends vs HSOS severity from Gao papers"

Research Agent → searchPapers('Gao pyrrole adducts HSOS') → Analysis Agent → runPythonAnalysis(pandas plot of concentrations from Gao 2011/2015) → matplotlib graph of dose-outcome correlations.

"Draft LaTeX review on PA herbal risks with imaging features"

Synthesis Agent → gap detection (therapeutics post-2014) → Writing Agent → latexEditText(intro on Huxtable 1992), latexSyncCitations(Zhou 2014), latexCompile → PDF with Zhou et al. CT figures.

"Find code for PA toxicity simulations in HSOS models"

Research Agent → paperExtractUrls(Neuman 2015) → Code Discovery → paperFindGithubRepo(toxicity sims) → githubRepoInspect → Python scripts for pyrrole adduct modeling.

Automated Workflows

Deep Research workflow scans 50+ PA papers via searchPapers, structures HSOS biomarker report with GRADE grading from Gao et al. (2015). DeepScan's 7-steps verify imaging claims (Zhou et al., 2014) via CoVe checkpoints. Theorizer generates hypotheses on PPA thresholds from Chojkier (2003) and Valla (2016).

Try Doxa for Hepatic Sinusoidal Obstruction Syndrome Pyrrolizidine Alkaloids Research

Frequently Asked Questions

What defines PA-induced HSOS?

PA-HSOS is veno-occlusive disease with sinusoidal obstruction from pyrrole-protein adducts, confirmed by elevated blood PPAs (Gao et al., 2011).

What are key diagnostic methods?

Blood PPA measurement by UPLC-MS/MS offers high sensitivity; histopathology shows endothelial damage (Gao et al., 2015; Chojkier, 2003).

Which papers set the field?

Ridker et al. (1985, 186 citations) links supplements to venocclusive disease; Huxtable (1992, 166 citations) exposes herbal myths; Stickel and Seitz (2000, 156 citations) details comfrey risks.

What open problems remain?

Therapeutic targets beyond supportive care; standardized PPA cutoffs for prognosis; PA metabolism variations across populations (Neuman et al., 2015; Larrey and Faure, 2010).